Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|90|11|1065-1070

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.11, 2015-11, pp. : 1065-1070

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment with FLT3 inhibitor in patients with FLT3‐mutated acute myeloid leukemia is associated with development of secondary FLT3–tyrosine kinase domain mutations

By  

CANCER, Vol. 120, Iss. 14, 2014-07 ,pp. : 2142-2149

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Surface Molecular Signature of Leukemic Cells Is Associated with NPM1 Mutations and FLT3-ITD in Patients with de novo Acute Myeloid Leukemia

By  

Acta Haematologica, Vol. 131, Iss. 3, 2013-10 ,pp. : 148-152

Karger

Access to resources Recommend Favorite

Independent oncogenic and therapeutic significance of phosphatase PRL‐3 in FLT3‐ITD–negative acute myeloid leukemia

By  

CANCER, Vol. 120, Iss. 14, 2014-07 ,pp. : 2130-2141

John Wiley & Sons Inc

Access to resources Recommend Favorite

Is allogeneic transplantation really the best treatment for FLT3/ITD‐positive acute myeloid leukemia? A systematic review

By  

CLINICAL TRANSPLANTATION (ELECTRONIC), Vol. 29, Iss. 2, 2015-02 ,pp. : 149-160

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 6, 2015-06 ,pp. : 1048-1054

John Wiley & Sons Inc

Access to resources Recommend Favorite